Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Document link: Pertuzumab for HER2+ Breast Cancer

(Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.)

Document Preview: